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Summary
Objective: The prevalence of osteoarthritis (OAs) increases with age and coincides with the accumulation of advanced glycation endproducts
(AGEs) in articular cartilage, suggesting that accumulation of glycation products may be involved in the development of OA. This study was
designed to examine the effects of accumulation of AGEs on the turnover of the extracellular matrix of human articular cartilage.
Design: Chondrocyte mediated cartilage degradation (GAG release, colorimetric) was measured in human articular cartilage of donors aged
19–82 years (N=30, 4-day culture). In addition, to mimic the age-related increase in AGE levels in vitro, cartilage was cultured in the absence
or presence of glucose, ribose or threose. Cartilage degradation and proteoglycan synthesis (35SO2−4 incorporation) were measured and
related to the degree of cartilage AGE levels (fluorescence at 360/460 nm).
Results: Chondrocyte-mediated degradation of articular cartilage (i.e. GAG release) decreased with increasing age of the cartilage donor
(r= −0.43, P<0.02). In vitro incubation of cartilage with glucose, ribose or threose resulted in a range of AGE levels that was highly correlated
to the chondrocyte-mediated cartilage degradation (r= −0.77, P<0.001, N=26). In addition, in these in vitro glycated cartilage samples, a
decrease in proteoglycan synthesis was observed at increasing AGE levels (r= −0.54, P<0.005, N=25).
Conclusions: This study shows that an increase in AGE levels negatively affects the proteoglycan synthesis and degradation of articular
cartilage. In combination, these two effects reduce the turnover of the cartilage and thereby the maintenance and repair capacity of the
tissue. By this mechanism, the age-related increase in cartilage AGE levels may contribute to the development of OA. © 2001 OsteoArthritis
Research Society International
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Osteoarthritis (OA) is one of the most common diseases of
the elderly: at age >60 years the majority of the population
has radiological OA in one or more joints1,2. Although its
role in the pathophysiology is largely unknown, age has
been recognized as one of the main risk factors for the
development of OA. Age-related changes in articular carti-
lage are therefore likely to play a role in the etiology of OA.
One of the major age-related changes in articular
cartilage is the accumulation of advanced glycation end-
products (AGEs), resulting from the spontaneous reaction
of reducing sugars with proteins3,4 The initial step in this
reaction is the formation of an unstable Schiff base through
the condensation of a sugar aldehyde with an -amino
group of (hydroxy)lysine or arginine residues in proteins.
Following this, the Schiff base is stabilized via an Amadori
rearrangement to form early glycation products that are still
reactive5. After a cascade of largely unknown reactions,720these early glycation products are ultimately converted into
a collection of fluorophores and chromophores, collectively
known as advanced glycation end-products (AGEs)4,6.
These AGEs form a heterogenous group of compounds
that include structurally characterized structures (e.g.
pentosidine) as well as chemically unidentified compounds.
Once formed, AGEs can only be removed from the body
when the protein involved is removed. Consequently,
although all proteins are prone to AGE formation, AGEs
accumulate especially in those with slow turnover7. From
age 20 onward (skeletal maturity), levels of AGEs increase
linearly with age in articular cartilage collagens and proteo-
glycans (∼20% of the AGEs is present in non-collagenous
proteins)7–11. This increase in AGE levels coincides with
the age-related increase in the incidence of OA, suggesting
that accumulation of AGEs may be involved development
of the disease.
Accumulation of AGEs is correlated with impaired bio-
mechanical properties in many tissues including arteries,
lens, tendon, skin and articular cartilage10,12–16. In
addition, AGEs affect the biochemical properties of pro-
teins: extracellular matrix susceptibility to degradation by
purified proteinases is decreased at elevated AGE levels in
lens capsule, basal membrane and skin17. At cellular
level18–20, AGE-modified proteins affect processes such as
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CARTILAGE SAMPLES
Macroscopically normal cartilage was obtained from
femoral condyles (N=30; 19–82 years) and humeral heads
(N=7; 46–64 years) post mortem at autopsy within 24 h
after death of the donors. Previous studies have shown
that this cartilage is biochemically normal, even if focal
OA lesions are present elsewhere in the joint27. Full thick-
ness cartilage was cut into square pieces (5–15 mg), which
were randomly divided over experimental conditions and
that were all individually handled. The cartilage explants
were cultured in Dulbecco’s Modified Eagle’s Medium
(GibcoBRL) supplemented with 0.85 mM ascorbic acid
(Sigma), 2 mM glutamin (GibcoBRL), 100 IU/ml sodium
benzylpenicillin, 100 IU/ml streptomycin sulfate and 10%
(v/v) heat inactivated adult pooled human male AB+ serum
(200 l/well, 37°C, 5% CO2 in air)9. To circumvent disturb-
ing effects of the initial tissue processing, cartilage was
always precultured for 16–24 h in culture medium. After
preculture, medium was replaced by fresh culture medium
and cartilage samples were cultured for 4 days.CARTILAGE DEGRADATION
To confirm that in our system GAG-release is largely
chondrocyte-dependent, the chondrocyte-mediated
release of glycosaminoglycans (GAGs) into the culture
medium (humeral head cartilage of four donors; 55±4
years) was compared to the loss of GAGs from non-viable
cartilage (N=3; 56±4 years). Cartilage was rendered
non-viable by freezing at −20°C followed by thawing
at room temperature, and this cycle was repeated
three times28. Subsequently, cartilage was washed and
incubated according to standard culture conditions.IN VITRO ENHANCEMENT OF AGE LEVELS
Humeral head cartilage (N=3 donors; 46, 52, 58 years,
N=12 samples per condition per donor) was incubated with
glucose (3, 10 and 30 mM), D(−)-ribose (3, 10 and 30 mM)
or threose (3 and 10 mM) to enhance AGE levels. Each
of these sugars has a different potency of glycation
and therefore this approach results in a quantitative andqualitative range of AGE levels, mimicking the diversity of
AGE found in vivo29,30.AGE MEASUREMENTS
AGEs form a heterogenous group of compounds
that include structurally characterized structures (e.g.
pentosidine) as well as chemically unidentified compounds.
Accumulation of AGEs has repeatedly been shown to result
in an increase in protein-bound fluorescence and
browning18,31–33. Therefore, to measure the overall level
of cartilage glycation rather than focusing on one of the
few characterized AGEs, cartilage AGE-fluorescence and
browning were determined using previously described
methods11,32,33. Cartilage samples (three samples per
condition per donor) were reduced overnight, sequentially
treated with chondroitinase ABC (Sigma), trypsin
(Boehringer Mannheim) and Streptomyces hyaluronidase
(Sigma), and solubilized by digestion with papain. In papain
digests, AGE specific absorption at 340 and 414 nm
(Titertek Multiskan MCC/340) and fluorescence (ex:
360 nm, em: 460 nm; CytofluorII, PerSeptive Biosystems)
were determined11. Modification of the amino acids
arginine and (hydroxy)lysine was determined in acid hydro-
lysates (6 N HCl, 18 h, 110°C) of the papain-digested
cartilage samples by RP-HPLC of 9-fluorenylmethyl chloro-
formate derivatized amino acids, as described previously34.
NEG parameters were expressed per amount of hydro-
xyproline (absorption and fluorescence) or per collagen
triple helix (amino acid modification; assuming 300
hydroxyproline residues per triple helix)35.PROTEOGLYCAN RELEASE
Cartilage degradation (N=9 samples per donor per
condition) was assessed by colorimetric assessment of
glycosaminoglycan (GAG) release into the culture
medium36. GAGs were precipitated and stained with
Alcian Blue dye solution (Sigma). Staining was quantified
photometrically by the change in absorbance at 620 nm
(Vitalab10, Vital Science, Dieren, The Netherlands).
Shark cartilage chondroitin sulfate (Sigma) served as a
standard. GAG release was normalized to the wet weight of
the cartilage samples36.PROTEOGLYCAN SYNTHESIS
As measure of proteoglycan synthetic activity the rate of
sulfate incorporation was determined (nine explants per
donor per condition) using carrier free 35SO2−4 (NEN
Dupont) during the last 4 h of the 4-day culture period.
After labeling, tissue digestion (papain) and precipitation
of glycosaminoglycans (cetylpyridiniumchloride, Sigma),
35SO2−4 incorporation was analysed by liquid scintillation
counting. Sulfate incorporation was calculated from the
35SO2−4 incorporation rate and the specific activity of the
culture medium and was expressed as nmol of sulfate
incorporated per hour per gram wet weight of tissue9,36.CYTOTOXICITY
Release of lactate dehydrogenase (LDH) into the culture
medium was determined as a measure of possible sugar-
induced cytotoxicity (Cytotoxicity kit, Boehringer). LDHthe synthesis of matrix components. AGE-modified albumin
has been reported to stimulate collagen type IV synthesis in
glomerular mesangial cells21,22. In contrast, mesangial
cells grown in the presence of glycating sugars or on
glycated matrix show decreased synthesis of collagen
types I and IV23. Type I collagen synthesis is also inhibited
in endothelial cells and in fibroblast cell lines upon
exposure to glycated albumin24,25.
The combined effects of AGEs on synthesis and
degradation of matrix constituents indicate that extracellu-
lar matrix turnover (i.e. matrix synthesis and degradation) is
affected by AGEs. Since articular cartilage is one of the
tissues containing the highest amounts of AGEs in the
body, AGE-related effects on extracellular matrix turnover
are likely to be of major importance in this tissue7,10,11,26.
Therefore, the present study was designed to investigate
the relation between AGE levels and chondrocyte-
mediated turnover of proteoglycans in human articular
cartilage.
722 J. DeGroot et al.: Glycation reduces cartilage turnoveractivity measurements were corrected for inhibition of LDH
activity as a result of glycation of LDH, using purified LDH
(Boehringer) incubated for 4 days in the presence or
absence of glucose (3, 10 and 30 mM), D(−)-ribose (3, 10
and 30 mM) or threose (3 and 10 mM) in culture medium.STATISTICAL ANALYSIS
Statistical evaluation was performed using SPSS soft-
ware version 10.0 (SPSS, Chicago, IL). Data are presented
as mean±S.E.M. Correlations between AGE parameters
were determined by bivariate correlation analysis
(Pearson). Relations between cartilage AGE levels and
proteoglycan synthesis or degradation were tested by
linear regression analysis. Differences between groups
were analyzed by Wilcoxon tests. P values less than
0.05 were considered to represent statistically significant
differences.ResultsEFFECT OF AGING
Chondrocyte-mediated cartilage degradation was
studied in human knee cartilage of donors of various ages.
With increasing donor age, a significant decrease in
chondrocyte-mediated GAG release was observed in
human articular cartilage (r= −0.43, P<0.02, N=30, 19–82
years, Fig. 1). To ensure that mainly chondrocyte-mediated
cartilage degradation rather than spontaneous loss of
GAGs was measured, cartilage degradation was compared
between cultured explants vs age-matched devitalized
explants (rendered non-viable by freeze-thawing).
Chondrocyte-mediated GAG release was four-fold higher
than spontaneous GAG release (P<0.05, Fig. 2), empha-sizing that in the human cartilage explant culture system
GAG release is mainly (>75%) chondrocyte-mediated.
To investigate whether the age-related decrease in GAG
release (Fig. 1) may be caused by an increase in cartilage
AGE levels in vitro enhancement of cartilage AGE levels
was employed.r = –0.43
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Fig. 1. GAG release decreases with donor age. Chondrocyte-
mediated release of GAGs from human femoral condyle cartilage
decreases with increasing donor age (N=30, 19–82 years). Each
symbol represents the average of at least eight individually
handled cartilage samples.0.0
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Fig. 2. Spontaneous loss of GAGs vs chondrocyte-mediated
cartilage degradation. GAG release into culture medium was
determined as a marker for matrix degradation in cartilage of which
cellular activity was abolished by freeze-thawing (spontaneous
GAG loss: N=3 donors, 56±4 years; nine samples per donor) and
in normally cultured explants (chondrocyte-mediated degradation:
N=4 donors, 55±4 years; nine samples per donor). Bars represent
mean values±S.E.M. The age did not differ between both groups
(P>0.8) Chondrocyte-mediated release of GAGs is four-fold
increased compared to the spontaneous GAG loss (P<0.05).AGE EFFECTS ON MATRIX DEGRADATION
Non-enzymatic glycation is initiated by many different
carbohydrates in vivo and results in a heterogeneous
collection of AGEs, few of which have been characterized4.
To mimic this in vivo situation, different reducing sugars
(glucose, ribose and threose) were used to initiate the AGE
formation in vitro. Consequently, general measures for
quantification of AGE levels (rather than a specific AGE)
were employed to examine the effects of AGEs37
Culture of human humeral head cartilage for 4 days
resulted in the release of ∼2.5 g GAG per mg cartilage into
the culture medium, in control conditions. This release was
decreased at increasing AGE levels, down to ∼1.0 g GAG
per mg cartilage at the highest AGE levels [Fig. 3(A)–(D)].
All the AGE measures, absorption at 340 and 414 nm
[Fig. 3(A),(B)], fluorescence [Fig. 3(C)] and amino acid
modification [Fig. 3(D)] showed a highly significant, nega-
tive linear correlation with GAG release (P<0.005 for all
parameters). All AGE measures showed highly significant
correlation to one another, indicating that in this study with
in vitro enhancement of AGE levels, these parameters are
interchangeable (bivariate Pearson correlation coefficients;
Table I).
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Fig. 3. Chondrocyte-mediated GAG release decreases with cartilage AGE levels. Each data point represents the mean of N=9 samples for
humeral head cartilage degradation (GAG release) and N=3 samples for AGE levels. GAG release decreases linearly with increasing AGE
levels, either determined as AGE related absorption at 340 nm (A), at 414 nm (B), fluorescence at 360/460 nm (C), or amino acid modification
(D). The correlation between matrix degradation and AGE levels is highly significant for all these AGE measures [(a)–(d); P<0.001].Table I
Pearson correlation coefficients of in vitro enhanced AGE levels in articular cartilage (by exposure to reducing
sugars)
Amino acid
modification
Absorption at
340 nm
Absorption at
414 nm
Absorption at 340 nm r=0.56
[per mol hydroxyproline] P<0.005
Absorption at 414 nm r=0.66 r=0.91
[per mol hydroxyproline] P<0.0005 P<0.0001
Fluorescence at 360/460 nm r=0.46 r=0.52 r=0.48
[RFU per nmol hydroxyproline] P<0.02 P<0.01 P<0.02
All AGE measures (absorption, fluorescence and amino acid modification) show strong and highly significant
correlations.
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In addition to matrix degradation, synthesis of cartilage
constituents is an important factor in the turnover of the
tissue. The effect of the heterogeneous collection of carti-
lage AGEs on the capacity of chondrocytes to synthesize
proteoglycans was therefore determined by measuring the
incorporation of the radioactive tracer 35SO2−4 . Concomitant
with the sugar-induced increase in AGE levels, a decrease
in proteoglycan synthesis was observed (Fig. 4; r= −0.54,
N=25, P<0.005, AGE-related fluorescence). These data
are consistent with previous observations using both a
different experimental approach (using only a concentration
range of ribose) and a different AGE marker (pentosidine)9.CHONDROCYTE VIABILITY
Previous studies showed that sugars are not cytotoxic in
the concentrations used9,21,38. In the present study, to
ensure that sugar-derived AGEs (and not the sugars them-
selves) were responsible for the decline in chondrocyte-
mediated cartilage turnover, cell death was assessed by
measurement of the plasma membrane integrity (release of
lactate dehydrogenase, LDH). At the sugar concentrations
used, no cytotoxicity was observed (nor by comparison of
different treatment groups by ANOVA P>0.05; nor by cor-
relating the LDH release to the AGE parameters: P>0.05
for all parameters).r = –0.54
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Fig. 4. Proteoglycan synthesis in human humeral head cartilage
after incubation with different sugars to enhance extracellular
matrix AGE levels. Each data point represents the mean of N=9
samples for proteoglycan synthesis (rate of 35SO2−4 incorporation)
and N=3 samples for AGE levels (AGE fluorescence). The
decrease in proteoglycan synthesis is significantly correlated to the
increase in AGE-fluorescence (P<0.005).Discussion
The maintenance of extracellular matrix integrity in
articular cartilage depends on the balance between syn-
thesis and degradation of matrix components. Thechondrocytes residing within the cartilage matrix are
responsible for maintaining this tight equilibrium. Due to the
avascular nature of cartilage, no other cell types contribute
to the internally regulated maintenance of the matrix39.
Changes in the capacity of chondrocytes to preserve their
extracellular matrix will therefore directly affect the quality
of the tissue.
With increasing age, the capacity of articular cartilage to
synthesize proteoglycans decreases9,40,41. Concomitantly,
the AGE levels of the tissue increase linearly with age from
20 years onward9–11. Previously, we showed that the level
of a specific AGE (i.e. pentosidine) is highly correlated with
the capacity of cartilage to synthesize proteoglycans9.
Employing a different approach by using different AGE
precursors (glucose, ribose and threose that generate a
wide variety of AGEs that are quantified with general AGE
measures), the present study shows that in vitro enhance-
ment of AGE levels results in decreased proteoglycan
synthesis.
In addition to the effects of AGEs on proteoglycan
synthesis, the current data show that chondrocyte-
mediated degradation of the cartilage matrix is severely
impaired at increased AGE levels. As yet, the exact mech-
anism by which AGE accumulation results in diminished
GAG release remains unclear. Accumulation of AGEs may
render proteins less susceptible to degradation by interfer-
ing with proteinase-substrate interactions: AGEs change
protein charge and conformation and/or may cause sterical
hindrance and thereby interfere with proteinase-substrate
interactions. In addition, increased inter- and intramolecular
AGE cross-links may diminish the release of degraded
cartilage constituents6.
Both synthesis, degradation, and removal of matrix con-
stituents such as collagens and proteoglycans are import-
ant features of physiological tissue turnover. In response to
external stimuli, chondrocytes adjust the surrounding
matrix to new requirements (e.g. response to differences in
loading regime)42–44 This adaptation of the articular carti-
lage structure is essential for the maintenance of a healthy
tissue capable to withstand the repetitive loading forces
intrinsic to the normal use of a joint. Decreased matrix
turnover due to the increased AGE levels may lead to a
less adequate response to stimuli, thus inferior cartilage
quality and consequently to enhanced susceptibility to
damage.
In addition to being indispensable for maintaining the
cartilage integrity under physiological conditions, synthesis
and degradation of matrix components also play a role in
the capacity of the tissue to repair damage during patho-
physiology. Degradation and removal of matrix proteins is
essential in repair processes after tissue injury. Damaged
tissue constituents are proteolytically cleaved, removed
and replaced by new, intact molecules. If removal and
replacement are hampered by the presence of AGEs,
repair will be slowed, and tissue damage is more likely to
progress. Moreover, AGEs can even be hypothesized to
amplify cartilage degeneration: due to AGE accumulation,
fragments of matrix constituents are less readily removed
and since cartilage degradation products have been shown
to stimulate chondrolysis, this may enhance cartilage
degradation45,46.
The increase in AGE levels has been shown to affect
the mechanical properties of articular cartilage: increased
tissue stiffness has been observed at increased AGE
levels, possibly leading to increased susceptibility
towards mechanically induced damage10. The increased
susceptibility towards mechanical damage, in combination
Osteoarthritis and Cartilage Vol. 9, No. 8 725with an AGE-dependent decrease in matrix turnover as
demonstrated in the present study, may contribute to the
development of OA with increasing age.Acknowledgments
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